Discovery of coumaric acid derivatives hinted by coastal marine source to seek for uric acid lowering agents

References

• Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661.
   PubMed Web of Science ®Google Scholar
• Tu YY. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 2011;17(10):1217–1220.
   PubMed Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharmaceut. 2002;235(1–2):179–192.
   PubMed Web of Science ®Google Scholar
• Patel M, Kumar R, Kishor K, Mlsna T, Pittman CU, Mohan D. Pharmaceuticals of emerging concern in aquatic systems: chemistry, occurrence, effects, and removal methods. Chem Rev. 2019;119(6):3510–3673.
   PubMed Web of Science ®Google Scholar
• Ruesgas-Ramon M, Figueroa-Espinoza MC, Durand E. Application of deep eutectic solvents (des) for phenolic compounds extraction: overview, challenges, and opportunities. J Agric Food Chem. 2017;65(18):3591–3601.
   PubMed Web of Science ®Google Scholar
• Balasundram N, Sundram K, Samman S. Phenolic compounds in plants and agri-industrial by-products: Antioxidant activity, occurrence, and potential uses. Food Chem. 2006;99(1):191–203.
   Web of Science ®Google Scholar
• von Nussbaum F, Brands M, Hinzen B, Weigand S, Häbich D. Antibacterial natural products in medicinal chemistry – exodus or revival? Angew Chem Int Ed Engl. 2006;45(31):5072–5129.
   PubMed Web of Science ®Google Scholar
• Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol. 2007;9(12):767–776.
   PubMed Web of Science ®Google Scholar
• Xu XH, Liu YF, Du GC, Ledesma-Amaro R, Liu L. Microbial chassis development for natural product biosynthesis. Trends Biotechnol. 2020;38(7):779–796.
   PubMed Web of Science ®Google Scholar
• Hu ZH, Qin P, Cai M, Xie M, Zhang KX. Anti-inflammatory activity of topically applied total flavonoids of Spartina alterniflora Loisel in vivo. J Plant Resour Environ. 1998;7:6–11.
   Google Scholar
• Bazzano M, Elmer W. Interactions and consequences of silicon, nitrogen, and Fusarium palustre on herbivory and DMSP levels of Spartina alterniflora. Estuar Coast Shelf S. 2017;198:106–113.
   Web of Science ®Google Scholar
• Qin P. Research Progress on the Relationship between Spartina alterniflora and Human Health. Chinese Wild Plant Resour. 2019; 38:70–73.
   Google Scholar
• Zhang HS, Zhang HY, Zai XM, Zhao F, Lei P, Liu C, Zhu CL, Qin P. Study on the effect of three natural compounds in Spartina alterniflora on uric acid. Chinese Wild Plant Resour. 2019;38:9–12.
   Google Scholar
• Pauff JM, Hille R. Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009;72(4):725–731.
   PubMed Web of Science ®Google Scholar
• He WW, Su GW, Sun-Waterhouse D, Waterhouse GIN, Zhao MM, Liu Y. In vivo anti-hyperuricemic and xanthine oxidase inhibitory properties of tuna protein hydrolysates and its isolated fractions. Food Chem. 2019;272:453–461.
   PubMed Web of Science ®Google Scholar
• Wang YJ, Zhang GW, Pan JH, Gong DM. Novel insights into the inhibitory mechanism of kaempferol on xanthine oxidase. J Agric Food Chem. 2015;63(2):526–534.
   PubMed Web of Science ®Google Scholar
• Schmidt HM, Kelley EE, Straub AC. The impact of xanthine oxidase (XO) on hemolytic diseases. Redox Biol. 2019;21:101072.
   PubMed Web of Science ®Google Scholar
• Wang J, Van Praagh A, Hamilton E, Wang Q, Zou BX, Muranjan M, Murphy NB, Black SJ. Serum xanthine oxidase: origin, regulation, and contribution to control of trypanosome parasitemia. Antioxid Redox Signal. 2002;4(1):161–178.
   PubMed Web of Science ®Google Scholar
• Lee BE, Toledo AH, Anaya-Prado R, Roach RR, Toledo-Pereyra LH. Allopurinol, xanthine oxidase, and cardiac ischemia. J Investig Med. 2009;57(8):902–909.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–1210.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, Sakamoto R. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in dbidb mice. Eur J Pharmacol. 2016;780:224–231.
   PubMed Web of Science ®Google Scholar
• Deswal S, Srivastava A. Role of allopurinol in optimizing thiopurine therapy in patients with autoimmune hepatitis: a review. J Clin Exp Hepatol. 2017;7(1):55–62.
   PubMedGoogle Scholar
• Mitsuboshi S, Yamada H, Nagai K, Okajima H. Comparison of clinical advantage between topiroxostat and febuxostat in hemodialysis patients. Biol Pharm Bull. 2017;40(9):1463–1467.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Maeda T, Hashimoto T, Nakagawa T, Ichikawa K, Sato Y, Kanno Y. Long-term safety and effectiveness of the xanthine oxidoreductase inhibitor, topiroxostat in Japanese hyperuricemic patients with or without gout: a 54-week open-label, multicenter, post-marketing observational study. Clin Drug Investig. 2020;40(9):847–859.
   PubMed Web of Science ®Google Scholar
• Yang YS, Wang B, Zhou KM, Liu JZ, Jiao QC, Qin P. Discovery of derivatives from Spartina alterniflora-sourced moiety as xanthine oxidase inhibitors to lower uric acid. Bioorg Med Chem Lett. 2022;73:128907.
   PubMed Web of Science ®Google Scholar
• Wei B, Zhou J, Xu JJ, Cui J, Ping FF, Ling JJ, Chen YJ. Discovery of coumarin-derived imino sulfonates as a novel class of potential cardioprotective agents. Eur J Med Chem. 2019;184:111779.
   PubMed Web of Science ®Google Scholar
• Bharate SS. Modulation of biopharmaceutical properties of drugs using sulfonate counterions: a critical analysis of FDA-approved pharmaceutical salts. J Drug Deliv Sci Tec. 2021;66:102913.
   Web of Science ®Google Scholar
• Cao H, Pauff JM, Hille R. X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin. J Nat Prod. 2014;77(7):1693–1699.
   PubMed Web of Science ®Google Scholar
• Wang B, Wang LR, Liu LL, Wang W, Man RJ, Zheng DJ, Deng YS, Yang YS, Xu C, Zhu HL. A novel series of benzothiazepine derivatives as tubulin polymerization inhibitors with anti-tumor potency. Bioorg Chem. 2021;108:104585.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tian JY, Cheng HZ, Yang YJ, Yang Y, Ye F, Xiao ZY. Identification of novel xanthine oxidase inhibitors via virtual screening with enhanced characterization of molybdopterin binding groups. Eur J Med Chem. 2022;230:114101.
   PubMed Web of Science ®Google Scholar
• Zhao JX, Mao Q, Lin FW, Zhang B, Sun M, Zhang TJ, Wang SJ. Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors. Eur J Med Chem. 2022;229:114086.
   PubMed Web of Science ®Google Scholar
• Lin HY, Han HW, Sun WX, Yang YS, Tang CY, Lu GH, Qi JL, Wang XM, Yang YH. Design and characterization of a-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors. Eur J Med Chem. 2018;144:137–150.
   PubMed Web of Science ®Google Scholar
• El-Adl K, El-Helby AGA, Ayyad RR, Mahdy HA, Khalifa MM, Elnagar HA, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Eissa IH. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4 (3H)-ones as potential VEGFR-2 inhibitors. Bioorg Med Chem. 2021;29:115872.
   PubMed Web of Science ®Google Scholar
• Li MH, Wu KR, Chen Z, Sun LY, Huang XQ, Hu XG, Lan T. Establishment and optimization of a hyperuricemic nephropathy mouse model. Acta Pharm Sin. 2022;57:1673–1678.
   Google Scholar
• Xu LQ, Lin GS, Yu QX, Mai LQ, Cheng LT, Xie JJ, Liu JH, Su YH, Li Yc ZR. Anti-hyperuricemic and nephroprotective effects of dihydroberberine in potassium oxonate- and hypoxanthine-induced hyperuricemic mice. Front Pharmacol 2021;12:645879.
   Google Scholar
• Niu YF, Zhou YF, Lin H, Gao LH, Xiong WY, Zhu HJ, Zou CG, Li L. Inhibition of 3,5,2',4'-tetrahydroxychalcone on production of uric acid in hypoxanthine-induced hyperuricemic mice. Biol Pharm Bull. 2018;41(1):99–105.
   PubMed Web of Science ®Google Scholar